REGN vs VRTX
Regeneron Pharmaceuticals and Vertex Pharmaceuticals, both Healthcare
Vertex Pharmaceuticals is the larger company at $115B against $64B. On trailing earnings REGN is the cheaper of the two at a P/E of 20.1 against 31.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year REGN returned +48% against +42% for VRTX. Ryufin's sector-relative Smart Score puts REGN ahead, 9/10 against 8/10.
| Figure | REGN | VRTX |
|---|---|---|
| Last close | $815 | $547 |
| Market cap | $64B | $115B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 20.1 | 31.9 |
| 1-year return | +48% | +42% |
| 5-year return | +43% | +171% |
| Ryufin Smart Scoresector-relative, 1–10 | 9/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Regeneron Pharmaceuticals
Revenue of $4.3B in Q2 2026, net income $1.3B. Its largest reported line is Share Of Profit Losses, 50% of the disclosed total.
Vertex Pharmaceuticals
Revenue of $3.3B in Q2 2026, net income $1.1B. Its largest reported line is TRIKAFTAKAFTRIO, 79% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.